Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03279055 · ClinicalTrials.gov registry record · NA

Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors

A NA study of Insomnia, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT03279055: Completed NA study of Insomnia, sponsored by Dana-Farber Cancer Institute.

NCT03279055 is a NA study of Insomnia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 22 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03279055, a NA study of Insomnia, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating a six-session online program designed to help insomnia (difficulty falling or staying asleep) in adolescent and young adult cancer survivors.

Primary Outcome

Insomnia symptom severity will be assessed using the Insomnia Severity Index

Conditions Studied

Interventions

  • BEHAVIORAL SHUTi

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2018-08-10
Est. Completion 2019-12-20
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT03279055 record still lists

NCT03279055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 1 intervention - of which SHUTi is the first listed.

NCT03279055 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03279055 about?

NCT03279055 is a clinical study titled "Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors". This research study is evaluating a six-session online program designed to help insomnia (difficulty falling or staying asleep) in adolescent and young adult cancer survivors.

What is the current status of trial NCT03279055?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2018-08-10. Estimated completion is 2019-12-20.

What conditions does trial NCT03279055 study?

This clinical trial studies the following conditions: Insomnia.

What interventions are being tested in trial NCT03279055?

The interventions under investigation include: SHUTi (BEHAVIORAL).

Who is sponsoring clinical trial NCT03279055?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03279055 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03279055's enrollment target sits among peer trials

22 134th of 151 higher than 17 of 151 other Insomnia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03279055, the US trial registry maintained by the National Library of Medicine. NCT03279055 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.